Veracyte Inc
12V
Company Profile
Business description
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Contact
6000 Shoreline Court
Suite 300
South San FranciscoCA94080
USAT: +1 650 243-6300
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
755
Stocks News & Analysis
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks
This US AI champion’s stock is too cheap to ignore
Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks
Why SpaceX is coming to your Super Fund
Most Australians will end up owning SpaceX — whether they like it or not.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,043.60 | 29.60 | -0.33% |
| CAC 40 | 8,467.98 | 37.19 | 0.44% |
| DAX 40 | 25,026.80 | 92.13 | 0.37% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,399.70 | 108.91 | -1.04% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,314.67 | 261.18 | 0.37% |
| NZX 50 Index | 13,443.58 | 80.27 | 0.60% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,826.40 | 30.20 | -0.34% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |